EIS-12656 / Eisbach Bio - LARVOL DELTA

Preclinical Characterization and Safety of First-in-Class, brain penetrant ALC1 Inhibitor EIS-12656 in HRD cancers (SABCS 2024) - "EIS-12656 is well absorbed, distributed, brain penetrant and accumulates in the tumor. Pharmacokinetic analysis indicated dose-proportional exposure and a half-life suitable for once-daily oral administration, providing a strong rationale for the currently recruiting Phase I/II clinical trial to further assess EIS-12656's safety and efficacy in biomarker selected oncology patients."

Preclinical • Breast Cancer • Oncology • PARP2

Eisbach Bio Secures CPRIT Grant to Advance Novel Cancer Therapeutic (GlobeNewswire) - "Eisbach Bio GmbH...is pleased to announce the receipt of a Texas Therapeutics Company Award from the Cancer Prevention and Research Institute of Texas (CPRIT). This prestigious grant of US$4.75 million will support the clinical development of Eisbach's first-in-class allosteric small molecule inhibitor EIS-12656 targeting ALC1, a chromatin remodeling enzyme and helicase that represents the molecular Achilles heel in a large subset of difficult-to-treat human cancers....The CPRIT grant will help support the work of Eisbach Bio during the Dose Expansion monotherapy Module 1 of its Phase I/II cancer trial, which is led by Dr. Timothy Yap of The University of Texas MD Anderson Cancer Center in Houston, Texas."

Financing • Oncology • Solid Tumor

Eisbach Bio Announces First Patient Dosed in Phase 1/2 Trial for EIS-12656, a First-In-Class Allosteric Inhibitor of ALC1 in Refractory Advanced Solid Tumors (GlobeNewswire) - "Eisbach Bio GmbH...announced that the first patient has been dosed in Module 1 of the ongoing Phase 1/2 MATCH clinical trial (NCT06525298) investigating the small molecule ALC1 inhibitor EIS-12656 in solid tumors."

Trial status • Oncology • Solid Tumor

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors (clinicaltrials.gov) - P1/2 | N=144 | Recruiting | Sponsor: Eisbach Bio GmbH

Combination therapy • New P1/2 trial • Oncology • Solid Tumor

Eisbach Bio announces FDA clearance of IND application for EIS-12656, a first-in-class allosteric inhibitor of ALC1 (PRNewswire) - "Eisbach Bio expects to start enrolling patients in the second quarter of 2024....Eisbach Bio GmbH...has announced United States Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application for EIS-12656, a small molecule inhibiting the chromatin helicase ALC1 (CHD1L)....The open label study of EIS-12656 will evaluate its safety, tolerability and efficacy in patients with genetically-defined advanced solid tumors."

IND • New P1/2 trial • Oncology • Solid Tumor